8月8日,强生公司(Johnson & Johnson)宣布,其创新治疗药物埃万妥单抗注射液正式获得中国国家药品监督管理局(NMPA)批准,联合甲磺酸兰泽替尼片适用于携带表皮生长因子受体(EGFR)19号外显子缺失或21号外显子L858R置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。此次获批标志着埃万妥单抗在中国迎来了今年第三个肺癌适应症。此前,埃万妥单抗已获批用于携带...
Source Link8月8日,强生公司(Johnson & Johnson)宣布,其创新治疗药物埃万妥单抗注射液正式获得中国国家药品监督管理局(NMPA)批准,联合甲磺酸兰泽替尼片适用于携带表皮生长因子受体(EGFR)19号外显子缺失或21号外显子L858R置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。此次获批标志着埃万妥单抗在中国迎来了今年第三个肺癌适应症。此前,埃万妥单抗已获批用于携带...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.